Brief: Cytomx Therapeutics Announces Business Update And Company Milestones For 2026
08/01/2026 13:32
Jan 8 (Reuters) - CytomX Therapeutics Inc CTMX.O: CYTOMX THERAPEUTICS ANNOUNCES BUSINESS UPDATE AND COMPANY MILESTONES FOR 2026 CYTOMX THERAPEUTICS INC - CX-2051 PHASE 1 DATA ON TRACK FOR Q1 2026 CYTOMX THERAPEUTICS: INITIAL CX-801 PHASE 1 COMBINATION DATA WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA EXPECTED BY END OF 2026 CYTOMX THERAPEUTICS INC - VARSETA-M PHASE 1 STUDY TO START IN Q1 2026 Source text: ID:nGNXbXfg40 Further company coverage: CTMX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway